Ongoing phase III studies in front-line advanced/metastatic RCC
| Study | Primary endpoint | Sample size | National clinical trial identifier | Start time/status |
|---|---|---|---|---|
| Nivolumab + ipilimumab vs. sunitinib | PFS, OS | 1070 (1:1) | NCT02231749 | Oct 2014/on-going/enrollment closed |
| Atezolizumab + bevacizumab vs. sunitinib | PFS, OS | 900 (1:1) | NCT02420821 | May 2015/on-going |
| Avelumab + axitinib vs. sunitinib | PFS, | 583 (1:1) | NCT02684006 | March 2016/on-going |
| Pembrolizumab + axitinib vs. sunitinib | PFS, OS | 840 (1;1) | NCT02853331 | Sept 2016 |
| Pembrolizumab + lenvatinib or everolimus + lenvatinib vs. sunitinib | PFS | 735 (1:1:1) | NCT02811861 | Sept 2016 |